Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Hanel

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Medicine|May 28, 2022
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future DirectionsJohn C Reneau, Polina Shindiapina, Zachary Braunstein, et al.
Leukemia & Lymphoma|December 14, 2023
Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomasZachary Braunstein, Allyson Waller, Emily Dotson, et al.
American Journal of Hematology|September 21, 2016
A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndromeWalter Hanel, Robert Briski, Charles W Ross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2007
Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptorJill M Kramer, Walter Hanel, Fang Shen, et al.
Blood Advances|October 26, 2022
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancyKaitlin Annunzio, Michael Cackovic, David Bond, et al.
Frontiers in Oncology|October 2, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemiaAnsel Nalin, Qiuhong Zhao, Timothy Voorhees, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2025
Resistance Mechanism for Zanubrutinib in Marginal Zone LymphomaJohn Sharp, Arwa Y Shana'ah, Timothy J Voorhees, et al.
Journal of Hematology & Oncology|January 5, 2025
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphomaSayan Mullick Chowdhury, Subodh Bhatta, Timothy J Voorhees, et al.
Hematological Oncology|November 11, 2021
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantationSairah Ahmed, Qiuhong Zhao, Walter Hanel, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|May 28, 2022
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future DirectionsJohn C Reneau, Polina Shindiapina, Zachary Braunstein, et al.
Leukemia & Lymphoma|December 14, 2023
Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomasZachary Braunstein, Allyson Waller, Emily Dotson, et al.
American Journal of Hematology|September 21, 2016
A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndromeWalter Hanel, Robert Briski, Charles W Ross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2007
Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptorJill M Kramer, Walter Hanel, Fang Shen, et al.
Blood Advances|October 26, 2022
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancyKaitlin Annunzio, Michael Cackovic, David Bond, et al.
Frontiers in Oncology|October 2, 2023
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemiaAnsel Nalin, Qiuhong Zhao, Timothy Voorhees, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2025
Resistance Mechanism for Zanubrutinib in Marginal Zone LymphomaJohn Sharp, Arwa Y Shana'ah, Timothy J Voorhees, et al.
Journal of Hematology & Oncology|January 5, 2025
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphomaSayan Mullick Chowdhury, Subodh Bhatta, Timothy J Voorhees, et al.
Hematological Oncology|November 11, 2021
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantationSairah Ahmed, Qiuhong Zhao, Walter Hanel, et al.
Pageof 5